ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bictegravir

Also written as “B/F/TAF”, “Bictegravir” and “BIC/LEN FDC”.

Its studies are mostly in Coinfection · Kidney Failure, Chronic · Mesothelioma, Malignant, led by 3 companies.

Drug pageBictegravir: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 23, 202325 company-led studies, 8 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences238 open or runningphase 4since Oct 23, 2023Oct 23, 2014Aug 2027phase 2 · NCT07645287
AGC Biologicsits history only10 open or runningphase 3since Mar 17, 2010Mar 17, 2010none ahead
Merckits history only10 open or runningphase 1since Apr 8, 2026Apr 8, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 10 earlier studies, Oct 23, 2014 to Jan 12, 2018.

  1. Jun 9, 2015Named bictegravirINNProposed as its International Nonproprietary Name in WHO's List 113
  2. May 24, 2018Phase 3 study in HIV-1/HBV Co-InfectionNCT03547908 · 244 enrolled · United States, China, Dominican Republic and more
  3. Aug 13, 2018Phase 3 study in HIV-1 InfectionNCT03631732 · 496 enrolled · United States
  4. May 21, 2019Phase 1 study in HIV-1-infectionNCT03960645 · 62 enrolled · United States, Dominican Republic, Thailand
  5. Oct 28, 2019Phase 2 study in HIV-1-infectionNCT04143594 · 183 enrolled · United States, Dominican Republic, Puerto Rico
  6. Aug 5, 2022Phase 3 study in HIV-1-infectionNCT05502341 · 689 enrolled · United States, Argentina, Australia and more
  7. Oct 23, 2023Phase 4 study in HIV-1-infectionNCT06104306 · 33 enrolled · United States, Canada, France
  8. Mar 20, 2024Phase 3 study in HIV-1-infectionNCT06333808 · 577 enrolled · United States, Argentina, Australia and more
  9. Jul 29, 2024Phase 3 study in HIV-1-infectionNCT06532656 · 75 enrolled · United States, Argentina, Italy and more
  10. Oct 4, 2024Phase 3 study in HIV-1-infectionNCT06630286 · 609 enrolled · United States, Argentina, Australia and more
  11. Jun 27, 2025Phase 1 study in HIV-1-infectionNCT07055451 · 16 enrolled · United States, South Africa
  12. Jun 8, 2026Phase 2 study in HIV-1-infectionNCT07645287 · 175 planned · United States, Australia, Canada and more
  13. Jul 13, 2026Phase 3 study in HIV-1-infectionNCT07708727 · 700 planned · United States, Canada, Germany and more
  14. Sep 29, 2026Primary completion moved from 2026-11 to 2030-07Date moved laterphase 3 · +44 months · NCT06532656
  15. Oct 26, 2026Phase 4 study in HIV-1 InfectionNCT07908446 · 400 planned

Ahead

  1. Aug 2027Primary completion: phase 2 study in HIV-1-infectionNCT07645287
  2. Mar 2028Primary completion: phase 1 study in HIV-1-infectionNCT07055451
  3. Jul 2028Primary completion: phase 4 study in HIV-1 InfectionNCT07908446
  4. Jul 2030Primary completion: phase 3 study in HIV-1-infectionNCT06532656

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 integrase inhibitor; Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule

Studies

All 23 Gilead Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07908446HIV-1 Infection4Not yet recruitingJul 2028400
NCT07708727HIV-1-infection · United States, Canada, Germany and more3RecruitingOct 2030700
NCT07645287HIV-1-infection · United States, Australia, Canada and more2RecruitingAug 2027175
NCT07055451HIV-1-infection · United States, South Africa1Active, not recruitingMar 202816
NCT06630286HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingApr 17, 2026609
NCT06532656HIV-1-infection · United States, Argentina, Italy and more3Active, not recruitingJul 203075
NCT06333808HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingOct 27, 2025577
NCT06104306HIV-1-infection · United States, Canada, France4CompletedJan 29, 202533
NCT05502341HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingSep 29, 2025689
NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico2CompletedOct 5, 2021183
NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand1CompletedJul 21, 202262
NCT03631732HIV-1 Infection · United States3CompletedAug 12, 2019496
NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more3CompletedFeb 25, 2022244
NCT03405935HIV-1 Infection · Belgium, France, Italy and more3CompletedNov 20, 201886
NCT03110380HIV-1-infection · United States, Austria, Canada and more3CompletedDec 4, 2018567
NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more3CompletedOct 9, 2017472
NCT02607956HIV-1 Infection · United States, Australia, Belgium and more3CompletedMay 12, 2017657
NCT02607930HIV-1 Infection · United States, Belgium, Canada and more3CompletedMay 9, 2017631
NCT02603120HIV-1 Infection · United States, Australia, Belgium and more3CompletedMay 9, 2017567
NCT02600819Kidney Failure, Chronic · United States, Austria, France and more3CompletedSep 29, 201755
NCT02397694HIV-1 Infection · United States2CompletedNov 30, 201598
NCT02400307HIV · United States, New Zealand1CompletedJul 6, 201519
NCT02275065HIV-1 Infection · United States1CompletedJan 23, 201523

How it is read

Names in the registry

  • “B/F/TAF”, 16 entries
  • “Bictegravir”, 3 entries
  • “BIC/LEN FDC”, 2 entries
  • “Bictegravir/Lenacapavir (BIC/LEN) FDC”, 2 entries
  • “Bictegravir/Lenacapavir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.